Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and delivering transformative therapies for rare diseases. The company's scientific focus is on therapeutic areas such as cholestasis, inborn errors of bile acid metabolism, and genetic neurology, with an emphasis on addressing unmet medical needs. Mirum's flagship medication, LIVMARLI, is available in the U. S. and the E. U. , while their pipeline features other promising candidates such as Volixibat, aimed at changing the trajectory of rare diseases. Driven by a passion for patients, Mirum Pharmaceuticals is committed to revitalizing communities affected by rare diseases through meaningful scientific discoveries and evidence-based therapies.